These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26258894)

  • 1. DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing.
    Nishina K; Piao W; Yoshida-Tanaka K; Sujino Y; Nishina T; Yamamoto T; Nitta K; Yoshioka K; Kuwahara H; Yasuhara H; Baba T; Ono F; Miyata K; Miyake K; Seth PP; Low A; Yoshida M; Bennett CF; Kataoka K; Mizusawa H; Obika S; Yokota T
    Nat Commun; 2015 Aug; 6():7969. PubMed ID: 26258894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA-RNA Heteroduplex Oligonucleotide for Highly Efficient Gene Silencing.
    Hara RI; Yoshioka K; Yokota T
    Methods Mol Biol; 2020; 2176():113-119. PubMed ID: 32865786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short DNA/RNA heteroduplex oligonucleotide interacting proteins are key regulators of target gene silencing.
    Asada K; Sakaue F; Nagata T; Zhang JC; Yoshida-Tanaka K; Abe A; Nawa M; Nishina K; Yokota T
    Nucleic Acids Res; 2021 May; 49(9):4864-4876. PubMed ID: 33928345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA/RNA heteroduplex oligonucleotide technology for regulating lymphocytes in vivo.
    Ohyagi M; Nagata T; Ihara K; Yoshida-Tanaka K; Nishi R; Miyata H; Abe A; Mabuchi Y; Akazawa C; Yokota T
    Nat Commun; 2021 Dec; 12(1):7344. PubMed ID: 34937876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly efficient silencing of microRNA by heteroduplex oligonucleotides.
    Yoshioka K; Kunieda T; Asami Y; Guo H; Miyata H; Yoshida-Tanaka K; Sujino Y; Piao W; Kuwahara H; Nishina K; Hara RI; Nagata T; Wada T; Obika S; Yokota T
    Nucleic Acids Res; 2019 Aug; 47(14):7321-7332. PubMed ID: 31214713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient Gene Suppression by DNA/DNA Double-Stranded Oligonucleotide In Vivo.
    Asami Y; Nagata T; Yoshioka K; Kunieda T; Yoshida-Tanaka K; Bennett CF; Seth PP; Yokota T
    Mol Ther; 2021 Feb; 29(2):838-847. PubMed ID: 33290725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly efficient gene silencing in mouse brain by overhanging-duplex oligonucleotides via intraventricular route.
    Lei Mon SS; Yoshioka K; Jia C; Kunieda T; Asami Y; Yoshida-Tanaka K; Piao W; Kuwahara H; Nishina K; Nagata T; Yokota T
    FEBS Lett; 2020 May; 594(9):1413-1423. PubMed ID: 31990989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective silencing of miR-126 after ischemic stroke by means of intravenous α-tocopherol-conjugated heteroduplex oligonucleotide in mice.
    Suzuki M; Ishibashi S; Iwasawa E; Oguma T; Saito Y; Li F; Otsu S; Ichinose K; Yoshioka K; Nagata T; Yokota T
    Sci Rep; 2021 Jul; 11(1):14237. PubMed ID: 34244578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense.
    Moschos SA; Frick M; Taylor B; Turnpenny P; Graves H; Spink KG; Brady K; Lamb D; Collins D; Rockel TD; Weber M; Lazari O; Perez-Tosar L; Fancy SA; Lapthorn C; Green MX; Evans S; Selby M; Jones G; Jones L; Kearney S; Mechiche H; Gikunju D; Subramanian R; Uhlmann E; Jurk M; Vollmer J; Ciaramella G; Yeadon M
    Mol Ther; 2011 Dec; 19(12):2163-8. PubMed ID: 21971426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates.
    Straarup EM; Fisker N; Hedtjärn M; Lindholm MW; Rosenbohm C; Aarup V; Hansen HF; Ørum H; Hansen JB; Koch T
    Nucleic Acids Res; 2010 Nov; 38(20):7100-11. PubMed ID: 20615897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric Antisense Oligonucleotide Conjugated to α-Tocopherol.
    Nishina T; Numata J; Nishina K; Yoshida-Tanaka K; Nitta K; Piao W; Iwata R; Ito S; Kuwahara H; Wada T; Mizusawa H; Yokota T
    Mol Ther Nucleic Acids; 2015 Jan; 4(1):e220. PubMed ID: 25584900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA/RNA heteroduplex technology with cationic oligopeptide reduces class-related adverse effects of nucleic acid drugs.
    Ohara M; Nagata T; Hara RI; Yoshida-Tanaka K; Toide N; Takagi K; Sato K; Takenaka T; Nakakariya M; Miyata K; Maeda Y; Toh K; Wada T; Yokota T
    Mol Ther Nucleic Acids; 2024 Sep; 35(3):102289. PubMed ID: 39252874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Separation-related rapid nuclear transport of DNA/RNA heteroduplex oligonucleotide: unveiling distinctive intracellular trafficking.
    Ono D; Asada K; Yui D; Sakaue F; Yoshioka K; Nagata T; Yokota T
    Mol Ther Nucleic Acids; 2021 Mar; 23():1360-1370. PubMed ID: 33738132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of activated microglia and macrophages by systemically administered DNA/RNA heteroduplex oligonucleotides.
    Nishi R; Ohyagi M; Nagata T; Mabuchi Y; Yokota T
    Mol Ther; 2022 Jun; 30(6):2210-2223. PubMed ID: 35189344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naked antisense double-stranded DNA oligonucleotide efficiently suppresses BCR-ABL positive leukemic cells.
    Hoshiko T; Kubota Y; Akisawa T; Watanabe T; Tanigawara K; Yano J; Kimura S
    Invest New Drugs; 2020 Aug; 38(4):1012-1019. PubMed ID: 31650445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice.
    Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B.
    Watanabe A; Nakajima M; Kasuya T; Onishi R; Kitade N; Mayumi K; Ikehara T; Kugimiya A
    J Pharmacol Exp Ther; 2016 May; 357(2):320-30. PubMed ID: 26907624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative Model Analysis and Simulation of Pharmacokinetics and
    Goto A; Yamamoto S; Igari T; Matsumoto SI; Chisaki I; Iida K; Nakayama M; Oda A; Kakoi Y; Uchida A; Miyata K; Nishikawa M; Nagata T; Kusuhara H; Yokota T; Hirabayashi H
    J Pharmacol Exp Ther; 2023 Jan; 384(1):197-204. PubMed ID: 36273821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.
    Prakash TP; Graham MJ; Yu J; Carty R; Low A; Chappell A; Schmidt K; Zhao C; Aghajan M; Murray HF; Riney S; Booten SL; Murray SF; Gaus H; Crosby J; Lima WF; Guo S; Monia BP; Swayze EE; Seth PP
    Nucleic Acids Res; 2014 Jul; 42(13):8796-807. PubMed ID: 24992960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol.
    Nishina K; Unno T; Uno Y; Kubodera T; Kanouchi T; Mizusawa H; Yokota T
    Mol Ther; 2008 Apr; 16(4):734-40. PubMed ID: 18362929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.